Geode Capital Management LLC increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 7.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 421,047 shares of the biotechnology company’s stock after buying an additional 29,603 shares during the period. Geode Capital Management LLC owned 0.77% of Sarepta Therapeutics worth $12,462,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 4.5% in the first quarter. Vanguard Group Inc. now owns 4,096,486 shares of the biotechnology company’s stock worth $121,256,000 after buying an additional 176,966 shares in the last quarter. Tekla Capital Management LLC boosted its stake in Sarepta Therapeutics by 9.7% in the first quarter. Tekla Capital Management LLC now owns 511,600 shares of the biotechnology company’s stock worth $15,143,000 after buying an additional 45,300 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,800 shares during the last quarter. Elk Creek Partners LLC boosted its stake in Sarepta Therapeutics by 77.8% in the first quarter. Elk Creek Partners LLC now owns 562,522 shares of the biotechnology company’s stock worth $16,651,000 after buying an additional 246,059 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Sarepta Therapeutics by 30.6% in the first quarter. Teachers Advisors LLC now owns 290,993 shares of the biotechnology company’s stock worth $8,613,000 after buying an additional 68,207 shares during the last quarter. Institutional investors and hedge funds own 63.11% of the company’s stock.

Shares of Sarepta Therapeutics, Inc. (NASDAQ SRPT) traded down 0.46% during trading on Friday, hitting $36.70. The company had a trading volume of 1,272,093 shares. The stock’s 50-day moving average is $37.48 and its 200 day moving average is $33.08. The firm’s market capitalization is $2.36 billion. Sarepta Therapeutics, Inc. has a 52-week low of $24.96 and a 52-week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. The company’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same period last year, the business earned ($1.19) earnings per share. Equities research analysts predict that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/19/geode-capital-management-llc-has-12-46-million-position-in-sarepta-therapeutics-inc-srpt-updated-updated-updated.html.

A number of research firms have recently weighed in on SRPT. Nomura reissued a “buy” rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, May 23rd. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 30th. Leerink Swann reissued an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, July 3rd. Credit Suisse Group set a $64.00 price objective on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Finally, Vetr cut Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price objective for the company. in a research report on Monday, May 22nd. Eight investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $61.28.

In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the transaction, the director now owns 62,471 shares in the company, valued at approximately $2,561,311. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was bought at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the acquisition, the chief executive officer now owns 382,058 shares in the company, valued at $16,237,465. The disclosure for this purchase can be found here. Insiders sold a total of 78,056 shares of company stock valued at $3,224,208 over the last ninety days. 9.60% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.